SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

China Medicine Corporation CHME OTC

Other OTC • Healthcare • Medical - Distribution • CN • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

China Medicine Corporation (CHME) is a Medical - Distribution company in the Healthcare sector, currently trading at $0.02. It has a SharesGrow Score of 65/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Financials: revenue is $65M, +41.2%/yr average growth. Net income is $2M, growing at -1.6%/yr. Net profit margin is 2.7% (thin). Gross margin is 29.3% (-8.1 pp trend).

Balance sheet: total debt is $10M against $45M equity (Debt-to-Equity (D/E) ratio 0.21, conservative). Current ratio is 2.1 (strong liquidity). Debt-to-assets is 14.2%. Total assets: $67M.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 100/100 (Pass), Health 100/100 (Pass), Moat 14/100 (Fail), Future ?/100 (Fail), Income 30/100 (Fail).

CHME SharesGrow Score Overview

67/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 58/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 14/100

Gross margin is + market cap

FUTURE 0/100

Analyst outlook — as buy

INCOME 30/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CHME

CHME trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

CHME: +41.2%/yr revenue is, -1.6%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

CHME: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet CHME: Debt-to-Equity (D/E) ratio 0.21 (conservative), Current ratio is 2.1 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

CHME: Gross margin is 29.3% (-8.1 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 14/100. ≥ 70 = Pass.

View details →

No analyst coverage available for this stock.

CHME: Net profit margin is 2.7%. thin (0-5%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.0001-0.042

Volume131.5K

Avg Volume (30D)1.93K

Market Cap$474.24K

Beta (1Y)11.80

Share Statistics

EPS (TTM)0.11

Shares Outstanding$15.27M

IPO Date2006-11-30

Employees281

CEOSenshan Yang

Financial Highlights & Ratios

Revenue (TTM)$64.75M

Gross Profit$18.98M

EBITDA$13.28M

Net Income$1.72M

Operating Income$12.27M

Total Cash$471.77K

Total Debt$9.51M

Net Debt$9.03M

Total Assets$66.84M

Price / Earnings (P/E)0.2

Price / Sales (P/S)0.01

Analyst Forecast

Company Info

CountryCN

ExchangeOther OTC

CurrencyUSD

ISINUS1694911074

Price Chart

CHME

China Medicine Corporation ↗ · Other OTC

Healthcare • Medical - Distribution

0.00 52WK RANGE 0.04

People Also View

Cardinal Health, Inc.

AmerisourceBergen Corporation

Henry Schein, Inc.

Patterson Companies, Inc.

Owens & Minor, Inc.

Eli Lilly and Company

Johnson & Johnson

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message